INDP
Indaptus Therapeutics Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$0.340
Kõrge
$0.340
Madal
$0.340
Maht
0.09M
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika
Seotud uudised
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today provided an
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20Pharmacodynamic immune activation biomarker and pharmacokinetics profiles in initial data
Registration Is Now Open For Tribe Public's Webinar Event "Keys To The Kingdom: Unlocking The Power Of Your Immune System" Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025
Meet with Indaptus Therapeutics' CEO Jeffrey MecklerRegister at INDP-KEYS.TribePublic.com NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) announces that Indaptus' CEO, Jeffrey
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.